OK, I'll get this thread started. I bought this stock in January based largely on the Barron's roundtable discussion of the stock in the January 19 issue. Since it has become public in the U.S. , it's done well but lacks the PR of domestic pharm. companies. It's got a nice pipeline of things coming along with a good clean balance sheet. So...anyone else care to jump in...particularily anyone from the U.K.?